We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pierre Fabre announced the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, a monoclonal antibody targeting VISTA, developed by ...